Results 81 to 90 of about 526 (152)

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary

What is this summary about? The SHARP study looked at the effects of a medication called solriamfetol in people with obstructive sleep apnea (sleep apnea for short) who were very sleepy during the day (called excessive daytime sleepiness) and had trouble
Tabuteau, Herriot, Van Dongen, Hans P. A., Bogan, Richard, Jaeger, Judith, Leary, Eileen B, Drake, Christopher L, Streicher, Caroline   +6 more
core  

A validated Rhodamine B fluorescence quenching spectrofluorimetric method for solriamfetol determination in human plasma with pharmacokinetic application. [PDF]

RSC Adv
Serag A, Felemban RA, Al Khzem AH, Alturki MS, Aldawsari MF, Alosaimi ME, Abduljabbar MH, Almalki AH.   +7 more
europepmc   +1 more source

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. [PDF]

CNS Drugs
Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, Tang S, Lv Y, Su X, Liu Z, Zhang X, Wang X, Mao H, Zhang N, Yu H, Pan J, Xie Y, Tang J, Yin S, Wang Z, Tong M, Zhan S, Wang C, Wang B, Zhang W, Mi W, Lu L.   +26 more
europepmc   +1 more source

Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies. [PDF]

J Pers Med
Siciliano M, de Scisciolo M, Fratini A, Sottani C, Giordani F, Brunetti V.   +5 more
europepmc   +1 more source

Relationship Between Efficacy Endpoints and Measures of Functional Status and Health-Related Quality of Life (HRQoL) in Obstructive Sleep Apnea patients Treated for Excessive Sleepiness

, 2018
Objectives/Introduction: A 12-week, double-blind, randomized, placebo-controlled Phase 3 trial in patients with obstructive sleep apnea associated with excessive sleepiness showed that solriamfetol doses 37.5, 75, 150 and 300 mg resulted in statistically
Villa, K F, Crosby, R D, Bron, M, Bujanover, S, Mathias, S D, Drake, Christopher L, Menno, D   +6 more
core  

Pitolisant Improves Depressive Symptoms in CPAP-Treated Patients with Obstructive Sleep Apnea and Severe Residual Sleepiness: First 12-Month Clinical Experience. [PDF]

CNS Drugs
Caratozzolo D, Muscato G, Rizzo P, Gangemi C, Scionti A, Mancuso S, Vancheri C, Spicuzza L.   +7 more
europepmc   +1 more source

Clinical pearls for the treatment of narcolepsy. [PDF]

Ment Health Clin
Bulloch MN, Geyer JD.
europepmc   +1 more source

Management of Central Disorders of Hypersomnolence in Pregnancy and Lactation. [PDF]

J Prim Care Community Health
Abideen ZU, Kolla BP, Bernard ME, Jegen DA, Furst JW, Mansukhani MP.   +5 more
europepmc   +1 more source

Drug Interactions With Excessive Daytime Sleepiness Treatments. [PDF]

J Pharm Technol
Thomas SV, Malesker MA, Hilleman DE, Dewan NA.   +3 more
europepmc   +1 more source

Patients with obstructive sleep apnea in Germany. [PDF]

Sleep Breath
Winter Y, Mayer G, Benes H, Burghaus L, Floam S, Parks GS, Kallweit U.   +6 more
europepmc   +1 more source